Egaptivon pegol

Drug Profile

Egaptivon pegol

Alternative Names: ARC1779

Latest Information Update: 12 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Archemix Corporation
  • Class Antithrombotics; Nucleotide aptamers; Polyethylene glycols
  • Mechanism of Action Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemolytic uraemic syndrome; Thrombosis; Thrombotic thrombocytopenic purpura; Von Willebrand disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Feb 2010 A phase IIa trial in cerebral embolism discontinued because of slow enrolment
  • 31 Mar 2009 Archemix initiates enrolment in a phase IIa trial for thrombosis prevention (in patients undergoing carotid endarterectomy) in Europe and North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top